-
Oppenheimer Calls Mallinckrodt's New Acthar Data 'Impressive,' Despite This Week's Turmoil
Wednesday, November 11, 2015 - 10:13am | 318Read More...Mallinckrodt PLC (NYSE: MNK) shares plummeted 37 percent, declining steeply from August through November. Oppenheimer’s Akiva Felt maintained an Outperform rating on the company, with a price target of $138. Two Acthar data presentations demonstrating early, yet impressive responses...
-
35 Stock Ideas Oppenheimer Analysts Love Right Now
Saturday, October 17, 2015 - 10:11pm | 1463Read More...Oppenheimer just released its 35 top stock ideas for October and November. Here’s a rundown of the full list with analyst commentary included. 1. Turtle Beach Corp (NASDAQ: HEAR) Analyst Sean McGowan sees two drivers of the stock: the “resurgence in video games” and the rollout of...
-
Watch Out Biotech Investors: Outrage Culture + Election Season = Ugly Rhetoric Ahead
Tuesday, September 22, 2015 - 10:46am | 406Read More...While shares of Biogen Inc (NASDAQ: BIIB), Mallinckrodt PLC (NYSE: MNK) and Pernix Therapeutics Holdings Inc (NASDAQ: PTX) have lost YTD, shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) have risen. Oppenheimer’s Akiva Felt has Outperform ratings on Mallinckrodt, Teva...
-
Oppenheimer: Time To Buy Tonix Pharmaceuticals
Sunday, June 14, 2015 - 10:51am | 260Read More...In a report published Friday, Oppenheimer analyst Akiva Felt initiated coverage of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) with an Outperform rating and a price target of $18. Analyst Akiva Felt believes that Tonix has been "overlooked" by investors after mixed Phase 2...
-
Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter
Thursday, April 30, 2015 - 4:25pm | 305Read More...Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)'s letter to Mylan NV (NASDAQ: MYL) suggests "much more commitment to pursuing a deal than we previously thought," an analyst said Thursday. Oppenheimer's Akiva Felt maintained an Outperform rating and $77 target on Teva and...
-
Exclusive: Oppenheimer Says Insys-Mallinckrodt Merger Not Any More Likely Than It Was 4 Months Ago
Wednesday, April 8, 2015 - 11:40am | 151Read More...A source familiar with the matter told Benzinga Tuesday that Mallinckrodt PLC (NYSE: MNK) was in talks to acquire Insys Therapeutics Inc (NASDAQ: INSY) in a transaction valuing shares at around $65. Shares of Insys were trading higher by more than 6 percent Wednesday. Speaking to Benzinga on...
-
8 Oppenheimer Analysts Choose Their Favorite Healthcare Stocks
Tuesday, March 31, 2015 - 12:04pm | 463Read More...In a recent report, Oppenheimer asked analysts that cover different areas of the stock market each to choose his or her single top stock pick in the space based on the company's fundamentals. Here are the stocks that Oppenheimer's eight analysts in the healthcare sector chose as top...
-
Oppenheimer: Teva Is Now Worth $77/Share, More Deals To Come
Tuesday, March 31, 2015 - 10:30am | 257Read More...Oppenheimer upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) Tuesday from Perform to Outperform and set a price target of $77. Analysts Akiva Felt and Angad Verma expected more deals to come following the announcement that the company would acquire Auspex Pharmaceuticals Inc (...
-
UPDATE: Oppenheimer Upgrades Zogenix Following Zohydro Approval
Thursday, November 14, 2013 - 8:09am | 118Read More...In a report published Thursday, Oppenheimer analyst Akiva Felt upgraded Zogenix (NASDAQ: ZGNX) from Perform to Outperform and moved the price target to $5.00. In the report, Oppenheimer wrote, "Zohydro's approval on 10/25 was a transformative event for Zogenix, in our view, and we are upgrading...
-
UPDATE: Oppenheimer Initiates Coverage on Cubist Pharmaceuticals on Strong Antibiotic Portfolio
Thursday, October 10, 2013 - 9:37am | 160Read More...In a report published Thursday, Oppenheimer analyst Akiva Felt initiated coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with an Outperform rating and $81.00 price target. In the report, Oppenheimer noted, “Cubist develops acute care drugs for the hospital setting, with an emphasis on...
-
Oppenheimer Reiterates Perform Rating on Amarin Following AMR-102 Study
Friday, June 21, 2013 - 11:22am | 151Read More...In a report published Friday, Oppenheimer analyst Akiva Felt reiterated a Perform rating and $8.00 price target on Amarin (NASDAQ: AMRN). In the report, Oppenheimer noted, “Amarin reported that the Phase 1 study of AMR-102 (fixed-dose combination of Vascepa+rosuvastatin) demonstrated positive...
-
UPDATE: Oppenheimer Assumes Zogenix at Perform on Fair Valuation
Friday, June 21, 2013 - 8:54am | 168Read More...In a report published Friday, Oppenheimer analyst Akiva Felt assumed coverage on Zogenix (NASDAQ: ZGNX) with a Perform rating. In the report, Oppenheimer noted, “We are assuming coverage of Zogenix with a Perform rating as we believe shares are fairly priced at current levels, largely...
-
UPDATE: Oppenheimer Assumes Viropharma at Outperform on Expected Improvement Ahead
Friday, June 21, 2013 - 8:52am | 157Read More...In a report published Friday, Oppenheimer analyst Akiva Felt assumed coverage on Viropharma (NASDAQ: VPHM) with an Outperform rating and $35.00 price target. In the report, Oppenheimer noted, “We are assuming coverage of ViroPharma and maintain our Outperform rating and $35 price target. For...
-
UPDATE: Oppenheimer Assumes Antares Pharma at Outperform on Multiple Positive Factors
Friday, June 21, 2013 - 8:42am | 184Read More...In a report published Friday, Oppenheimer analyst Akiva Felt assumed coverage on Antares Pharma (NASDAQ: ATRS) with an Outperform rating and $6.00 price target. In the report, Oppenheimer noted, “We are assuming coverage of Antares Pharma (ATRS) with an Outperform rating and a 12- to 18-month...
-
UPDATE: Oppenheimer Assumes Endo Health Solutions at Perform on Operational Restructuring
Friday, June 21, 2013 - 8:37am | 167Read More...In a report published Friday, Oppenheimer analyst Akiva Felt assumed coverage on Endo Health Solutions (NASDAQ: ENDP) with a Perform rating. In the report, Oppenheimer noted, “We are assuming coverage of Endo Health Solutions (ENDP) with a Perform rating. We remain on the sidelines as the...
